SOLO-2 Results: Maintenance Therapy with Lynparza Extends Survival in Relapsed Ovarian Cancer

SOLO-2 Results: Maintenance Therapy with Lynparza Extends Survival in Relapsed Ovarian Cancer
Maintenance therapy with AstraZeneca’s Lynparza (olaparib) extended survival by more than one year in women with BRCA-mutated relapsed ovarian cancer, whose tumors responded to platinum-based chemotherapy, final results from the SOLO-2 Phase 3 clinical trial show. Trial findings, Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation," will be presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held online May 29–31. A video presentation is available now. Lynparza is a so-called PARP inhibitor as it works by blocking the PARP enzyme, which plays a role in repairing DNA errors in cel
Subscribe or to access all post and page content.